A phase I/II trial of VR-CHOP [bortezomib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone] for patients with untreated follicular lymphoma and other low grade B-cell lymphomas.

Trial Profile

A phase I/II trial of VR-CHOP [bortezomib + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone] for patients with untreated follicular lymphoma and other low grade B-cell lymphomas.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Oct 2016

At a glance

  • Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
  • Indications Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Mar 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 05 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Feb 2015 to 1 Dec 2015.
    • 05 Mar 2015 According to the ClinicalTrials.gov record, planned primary completion date changed to 1 Dec 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top